Brief: Obseva Announces UK MHRA Marketing Authorization For Yselty® (Linzagolix)
28/06/2022 21:05
June 28 (Reuters) - Obseva SA OBSN.S :
* OBSEVA ANNOUNCES UK MHRA MARKETING AUTHORIZATION FOR
YSELTY®
(LINZAGOLIX), AN ORAL GNRH ANTAGONIST, FOR THE TREATMENT OF
UTERINE FIBROIDS
* OBSEVA SA - THERAMEX TO COMMERCIALIZE YSELTY®; OBSEVA TO
RECEIVE
ROYALTIES ON COMMERCIAL SALES
Source text for Eikon: ID:nGNE6C2kmp
Further company coverage: OBSN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary